$PRFX Phase I safety data just dropped.

PRFX just reported positive Phase I safety data for its OcuRing-K drop-less ocular drug platform. The study showed no serious adverse events, no treatment-related safety issues, and proper device positioning in cataract surgery patients. Reuters and TipRanks picked it up, and the company explicitly tied the results to advancing toward an IND submission and Phase II development. The idea here is replacing weeks of post-op eye drops with a single, sustained-release solution placed during surgery. The News will catch on. It's still early and the chart has not yet reacted. Alongside the pharma side, they own "... DeepSolar, which is already operating as a commercial solar analytics and due-diligence platform used in utility-scale solar asset evaluations." It’s an unusual mix, but it means the company isn’t completely dependent on its OcuRing. Pretty cool.